The CEO shared growing momentum for AI security, describing Okta Secures AI as "a significant new opportunity and a catalyst for growth." He said, "We have already been engaged with over 100 of our ...

The company expects low to mid-teens sequential net new ARR growth from Q3 to Q4, with FY '26 ending ARR growth targeted at 23% year-over-year. At the midpoint of its net new ARR assumptions, ...

Marvell delivered $2.075 billion in revenue in Q3, with data center revenue at $1.52 billion, representing 2% sequential growth and 38% year-over-year growth. Communications and other end market ...

Anavex Life Sciences' Phase 2B/3 trial failed to achieve statistical significance on both primary endpoints. Read why I ...

Simulations Plus' silico software boosts non-animal drug development and drives growth. Read here for an investment analysis ...

DTD's estimated yield is only 2.09%, but its current portfolio provides a solid foundation for future dividend growth. Read ...

Discover if the JPMorgan Equity Premium Income Fund (JEPI) fits your income strategy. Learn its pros, cons, and performance ...

Concentrix may offer value after an 80% drop. Click to learn about CNXC stock's earnings forecasts, insider buying, and ...

Prem Watsa’s Fairfax Financial Holdings 13F portfolio rose to $2.06B in Q3 2025. Click here to read more about the portfolio.

Caleres, Inc. faces heightened risk after acquiring loss-making Stuart Weitzman. Click here to read why CAL stock is a Hold.

Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential ...

The Invesco DJD ETF is upgraded to "Buy" for 2026 alpha, with low P/E, strong momentum, and a $63 target. Here's what you ...